Author Archives: Lu Rahman

#AI / data analytics / healthtech / informatics #Clinical trials

Healthtech specialist Novadiscovery teams up with with Janssen France

Novadiscovery, a healthtech company offering the clinical trial simulation platform, Jinkō, to predict drug efficacy and optimize clinical trial development, has entered into a collaboration with Janssen France to provide in silico based decision support for its clinical development pipeline. Novadiscovery is committed to working with forward-looking industry leaders to… Read More

#News

#Drug development #Drug discovery #Target validation

Evotec milestones in Bristol Myers Squibb collaboration

Evotec has achieved key milestones in its partnership with Bristol Myers Squibb in the field of targeted protein degradation with the first two targets transitioning into drug discovery after completing a comprehensive target validation process. Evotec and Bristol Myers Squibb (the successor in interest to Celgene) initiated their long-term strategic… Read More

#News

#Covid-19 #Organ-on-a-chip #Therapeutics

CN Bio and University of Melbourne collaborate on COVID-19 therapies

CN Bio has announced a collaboration with the University of Melbourne, focused on respiratory therapies for recovering COVID-19 patients. Harnessing CN Bio’s organ-on-a-chip technology, the aim of the research is to develop a model capable of recapitulating the fibrosis and tissue remodelling seen in chronic interstitial lung disease, often occurring… Read More

#Editor's Choice #News

#Drug development

Galapagos and Gilead Sciences in new agreement

Gilead Sciences and Galapagos have agreed to amend their existing arrangement for the commercialisation and development of Jyseleca (filgotinib). This announcement follows a meeting with the US FDA related to the New Drug Application (NDA) for filgotinib in the treatment of rheumatoid arthritis (RA.) Based on the feedback received from the… Read More

#News

#Antibody #Biologics #Drug discovery #High throughput screening

PerkinElmer invests in Carterra, antibody screening and characterisation expert

Carterra, specialist in label-free high throughput antibody screening and characterisation, has closed on a round of equity financing led by PerkinElmer. Current Carterra investors Telegraph Hill Partners and Ballast Point Ventures also participated in the financing round. The Carterra LSA platform for accelerating the discovery of therapeutic antibodies has become… Read More

#Editor's Choice #News

#AI / data analytics / healthtech / informatics #Antibodies #Biotechnology #Cancer research #Drug development #Oncology

AI-driven precision medicine for development of HMBD-001 in HER3-driven cancers

Hummingbird Bioscience, a clinical-stage biotech company focused on developing revolutionary therapies for hard-to-drug targets, is collaborating with Tempus, an expert in artificial intelligence and precision medicine. This will drive the development of Hummingbird’s lead clinical program, HMBD-001, as it advances into clinical trials in HER3-driven cancers, including those that harbour… Read More

#Cancer Research #News

#Drug development #Immune system

Schizophrenia may be similar to immune disorders, say scientists

A study by clinical scientists at The University of Manchester has shown that schizophrenia may – in some part – be caused by disordered functioning of the immune system. The first ever trial in schizophrenia of the powerful immune suppressant drug, Methotrexate, produced what the team described as ‘promising’ effects… Read More

#Editor's Choice #News

#AI / data analytics / healthtech / informatics #CRO

CRO undergoes digital data transformation: a case study

Jubilant Biosys improves data management, research productivity, and customer satisfaction with an informatics platform Jubilant Biosys, an international contract research organisation (CRO), has provided drug discovery and contract research services to the global pharmaceutical industry for 20 years. Headquartered in Noida, India with additional facilities in Bengaluru, the company’s 600-plus… Read More

#Exclusive Content

#AI / data analytics / healthtech / informatics #Biomarkers #Drug discovery

2020 overview for AI for drug discovery, biomarker development and advanced R&D

Deep Pharma Intelligence announces the release of a new, open-access 130-page analytical report and interactive analytics Dashboard: AI for Drug Discovery, Biomarker Development and Advanced R&D Landscape Overview 2020. This delivers advanced market intelligence, interactive mindmaps, benchmarking for companies, investors and technologies, competitive and SWOT analysis through the interactive IT-Platform and… Read More

#Editor's Choice #Market Reports #News

#Covid-19 #Immunology / Virology & Vaccines

Sanofi and GSK COVID-19 vaccine delayed

Sanofi and GSK have announced a delay in their adjuvanted recombinant protein-based COVID-19 vaccine program to improve immune response in older adults. Phase I/II study interim results showed an immune response comparable to patients who recovered from COVID-19 in adults aged 18 to 49 years, but a low immune response… Read More

#Covid-19 #Editor's Choice #News #Trending News

#Antibodies #Covid-19 #Novel therapeutics

Fusion Antibodies and Queen’s University get grant to develop COVID-19 antibodies

Fusion Antibodies, pre-clinical antibody discovery, engineering and supply experts, and Queen’s University Belfast, have been awarded a £453,000 grant from Invest Northern Ireland to further expand their COVID-19 targeted research and development efforts. Within the framework of their Northern Ireland Coronavirus Antibody Development Alliance (NICADA), the two organisations will use… Read More

#Covid-19 #Editor's Choice #News